ARCHIVES

Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: FDA Names DeLap Directory Of Oncology

June 7, 1996

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

August 30, 2013

Foundation Issues Call For Tobacco Policy Research Proposals

November 27, 1992

Robert Day Named New Director At Hutchinson Center

June 19, 1981

NCI-Approved Clinical Trials Begun At Groups, Centers

November 30, 2007

Upton Closer To Decision On Control, Centers Merger; ACCC Defeats Motion In Opposition

March 16, 1979